U.S. Department of Energy and Kyoto Fusioneering Launch Strategic Partnership to Build Critical Fusion Infrastructure and Accelerate Deployment of Commercial Fusion Power
29.1.2026 14:00:00 CET | Business Wire | Press release
Today, the U.S. Department of Energy (DOE) and Kyoto Fusioneering (KF) established a landmark partnership to deliver critical fusion infrastructure and perform collaborative R&D to drive down technology and commercialization risk.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127164854/en/

Anchored by a new public-private partnership between KF and Oak Ridge National Laboratory (ORNL) that leverages each institution’s expertise in fusion technology to develop world-leading fusion test facilities and technology, this agreement establishes a new paradigm in U.S.-Japan allied cooperation and public-private partnership towards accelerating the deployment of commercial fusion power.
Under the new partnership, KF and ORNL will commence joint research and development activities focused on fusion breeding blanket systems, a critical technology for producing the tritium fuel needed to sustain fusion power generation. This includes laying the groundwork for the joint development of UNITY-3, a world leading breeding blanket test facility to be built at ORNL. KF and ORNL will immediately begin work to deliver UNITY-3 as a next-generation flexible fusion nuclear platform. The facility is designed to validate tritium breeding blanket performance with prototypic neutrons and component geometries, a critical step towards delivering commercial power plants. Underscoring the urgent market demand for this capability, the initiative has garnered strong industry endorsement from ten partners, including seven leading U.S. fusion development programs.
In parallel, KF and ORNL will work with Idaho National Laboratory (INL) and Savannah River National Laboratory (SRNL) to leverage KF’s complementary UNITY-1 and UNITY-2 facilities in Japan and Canada, respectively, for non-nuclear blanket, thermal cycle, and tritium fuel cycle technology development, all part of DOE’s Tritium Blanket Development Platform under the Fusion Nuclear Science mission.
This partnership unites the DOE’s Tritium Blanket Development Platform(TBDP) and KF’s global Unique Integrated Testing Facility(UNITY™) programs to execute on the Build-Innovate-Grow strategy to close critical gaps identified in the DOE Office of Science’s Fusion Science & Technology Roadmap. These programs systematically elevate technology readiness level (TRL) of the tritium breeding blanket and fuel cycle systems by delivering logically linked, increasingly prototypic test environments and exploiting them through private-led and public-enabled coordination.
This agreement pioneers a model for coordinated public-private investment and international collaboration. Led by a market-driven commercial imperative and enabled by world-leading science, the partnership merges KF’s engineering and fusion technology excellence with the scientific pedigree of the DOE national laboratories. This synergy strengthens the deep strategic bond between the U.S. and Japan, pooling allied resources to forge a fusion industrial base unrivaled across the globe.
“Fusion energy represents a transformational opportunity for our energy future,” said Dr. Darío Gil, DOE Under Secretary for Science. “This partnership reflects DOE’s commitment to working with trusted allies and the private sector to build critical infrastructure, strengthen American competitiveness, and deliver real, measurable progress toward making fusion energy a reality.”
“The United States and Japan share a long history of close cooperation in science and technology,” said Dr.Satoshi Konishi, Co-Founder and CEO of Kyoto Fusioneering. “Through this strategic partnership with DOE, we are proud to contribute KF and Japan’s fusion technology and engineering expertise to advance fusion nuclear science, reduce risk for fusion power plants, and support the long-term success of the U.S. and Japanese fusion ecosystems.”
About U.S. Department of Energy Office of Science
DOE’s Office of Science (SC) is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time. Its Fusion Energy Sciences (FES) program is actively executing the Fusion Science & Technology Roadmap to accelerate the delivery of commercial fusion power. For more information, please visit https://www.energy.gov/science.
About Kyoto Fusioneering
Kyoto Fusioneering (KF) is the world’s premier fusion technology and integrated systems provider, supporting many of the world’s most advanced private and public fusion programs. As the largest fusion company to emerge from Japan, KF delivers critical-path technologies—including plasma heating, thermal management, and fuel cycle systems—essential for commercial fusion power. Headquartered in Tokyo, KF operates globally with subsidiaries in the United States, the United Kingdom, and the European Union, and a joint venture in Canada.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260127164854/en/



Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom